Evidence map›Paper›PMID 39440304›Full record

ArticleBrain communications2024

Axonal damage and inflammation response are biological correlates of decline in small-world values: a cohort study in autosomal dominant Alzheimer's disease.

Lisa Vermunt, Courtney L Sutphen, Ellen Dicks, Diederick M de Leeuw, Ricardo F Allegri, Sarah B Berman, David M Cash, Jasmeer P Chhatwal, Carlos Cruchaga, Gregory S Day and 28 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Lisa VermuntAlzheimer center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Programme Neurodegeneration, Amsterdam University Medical Centers, Vrije Universiteit, 1081 HZ Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0001-7420-6384
Courtney L SutphenWashington University School of Medicine, St. Louis, MO 63110, USA.
Ellen DicksAlzheimer center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Programme Neurodegeneration, Amsterdam University Medical Centers, Vrije Universiteit, 1081 HZ Amsterdam, The Netherlands.
Diederick M de LeeuwAlzheimer center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Programme Neurodegeneration, Amsterdam University Medical Centers, Vrije Universiteit, 1081 HZ Amsterdam, The Netherlands.ORCID https://orcid.org/0009-0007-8410-5078
Ricardo F AllegriInstituto de Investigaciones Neurológicas FLENI, Buenos Aires, Argentina.
Sarah B BermanDepartment of Neurology, Alzheimer's Disease Research Center, and Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA 15213, USA.
David M CashDementia Research Centre, UCL Queen Square Institute of Neurology, London WC1N 3AR, UK.ORCID https://orcid.org/0000-0001-7833-616X
Jasmeer P ChhatwalDepartment of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.ORCID https://orcid.org/0000-0002-7792-1698
Carlos CruchagaWashington University School of Medicine, St. Louis, MO 63110, USA.ORCID https://orcid.org/0000-0002-0276-2899
Gregory S DayMayo Clinic Florida, Jacksonville, FL 32224, USA.
Michael EwersInstitute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilian-University Munich, 81377 Munich, Germany.ORCID https://orcid.org/0000-0001-5231-1714
Martin R FarlowDepartment of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN 46202, USA.
Nick C FoxDementia Research Institute at UCL, University College London Institute of Neurology, London W1T 7NF, UK.
Bernardino GhettiSection for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, 72076 Tübingen, Germany.
Neill R Graff-RadfordMayo Clinic Florida, Jacksonville, FL 32224, USA.
Jason HassenstabWashington University School of Medicine, St. Louis, MO 63110, USA.
Mathias JuckerGerman Center for Neurodegenerative Diseases (DZNE), 37075 Göttingen, Germany.
Celeste M KarchWashington University School of Medicine, St. Louis, MO 63110, USA.
Jens KuhleNeurologic Clinic and Policlinic, University Hospital and University Basel, 4031 Basel, Switzerland.ORCID https://orcid.org/0000-0002-6963-8892
Christoph LaskeGerman Center for Neurodegenerative Diseases (DZNE), 37075 Göttingen, Germany.
Johannes LevinGerman Center for Neurodegenerative Diseases (DZNE), 37075 Göttingen, Germany.
Colin L MastersFlorey Institute, Melbourne, Parkville Vic 3052, Australia.ORCID https://orcid.org/0000-0003-3072-7940
Eric McDadeWashington University School of Medicine, St. Louis, MO 63110, USA.
Hiroshi MoriDepartment of Clinical Neuroscience, Osaka City University Medical School, 558-8585 Osaka, Japan.
John C MorrisWashington University School of Medicine, St. Louis, MO 63110, USA.ORCID https://orcid.org/0000-0001-9820-5618
Richard J PerrinWashington University School of Medicine, St. Louis, MO 63110, USA.
Oliver PreischeGerman Center for Neurodegenerative Diseases (DZNE), 37075 Göttingen, Germany.
Peter R SchofieldNeuroscience Research Australia & School of Medical Sciences, NSW 2052 Sydney, Sydney, Australia.
Marc Suárez-CalvetBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, 08005 Barcelona, Spain.
Chengjie XiongWashington University School of Medicine, St. Louis, MO 63110, USA.
Philip ScheltensAlzheimer center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Programme Neurodegeneration, Amsterdam University Medical Centers, Vrije Universiteit, 1081 HZ Amsterdam, The Netherlands.
Charlotte E TeunissenNeurochemistry Laboratory, Departmentt of Laboratory Medicine, Amsterdam Neuroscience, Programme Neurodegeneration, Amsterdam University Medical Centers, Vrije Universiteit, 1081 HZ Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-4061-0837
Pieter Jelle VisserDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, 6229 ER Maastricht, Netherlands.
Randall J BatemanWashington University School of Medicine, St. Louis, MO 63110, USA.ORCID https://orcid.org/0000-0002-7729-1702
Tammie L S BenzingerWashington University School of Medicine, St. Louis, MO 63110, USA.
Anne M FaganWashington University School of Medicine, St. Louis, MO 63110, USA.
Brian A GordonWashington University School of Medicine, St. Louis, MO 63110, USA.ORCID https://orcid.org/0000-0003-2109-2955
Betty M TijmsAlzheimer center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Programme Neurodegeneration, Amsterdam University Medical Centers, Vrije Universiteit, 1081 HZ Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-2612-1797

Funding

Dominantly Inherited Alzheimer NetworkUF1AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2014 to 2017
$21.6M
HIGH PERFORMANCE BIOMEDICAL IMAGING COMPUTER RESOURCESS10RR022984 · NCRR · WASHINGTON UNIVERSITY · PI PRIOR, FRED WILLIAM · 2009 to 2009
$1.9M
Neuroimaging Markers of Emerging Dysfunction In Preclinical Alzheimer DiseaseK01AG053474 · NIA · WASHINGTON UNIVERSITY · PI GORDON, BRIAN ANDREW · 2017 to 2021
$623k
GPU COMPUTING RESOURCE TO ENABLE INNOVATION IN IMAGING AND NETWORK BIOLOGYS10OD018091 · OD · WASHINGTON UNIVERSITY · PI PAPPU, ROHIT V, PRIOR, FRED WILLIAM · 2014 to 2014
$598k
NCRR NIH HHS S10 RR022984NIA NIH HHS K01 AG053474NIA NIH HHS UF1 AG032438NIH HHS S10 OD018091
6 · The paper itself

Abstract

The grey matter of the brain develops and declines in coordinated patterns during the lifespan. Such covariation patterns of grey matter structure can be quantified as grey matter networks, which can be measured with magnetic resonance imaging. In Alzheimer's disease, the global organization of grey matter networks becomes more random, which is captured by a decline in the small-world coefficient. Such decline in the small-world value has been robustly associated with cognitive decline across clinical stages of Alzheimer's disease. The biological mechanisms causing this decline in small-world values remain unknown. Cerebrospinal fluid (CSF) protein biomarkers are available for studying diverse pathological mechanisms in humans and can provide insight into decline. We investigated the relationships between 10 CSF proteins and small-world coefficient in mutation carriers (

Indexed as

autosomal dominant Alzheimer diseaseaxonal damageinflammationneuronal injurystructural covariance network

Identifiers

PMID39440304
PMCPMC11495221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.